3 October 2024 F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic.
Privately-held Chinese developer of molecular glue degraders for cancer treatment Degron Therapeutics has entered into a collaboration and exclusive license agreement with Japan’s largest drugmaker Takeda Pharma. 23 May 2024
Basel, Switzerland-based SixPeaks Bio emerged from stealth mode yesterday, with a pipeline of therapies for healthy weight loss, including a potentially best-in-class dual-specific antibody targeting activin type IIA and B receptors. 23 May 2024
MilliporeSigma, the US and Canada Life Science business of Germany’s Merck KGaA, has signed a definitive agreement to acquire USA-based Mirus Bio, a specialist in the development and commercialization of transfection reagents. 23 May 2024
The US National Institutes of Health (NIH) has issued a first-of-its-kind draft policy proposal to promote equal access to products stemming from NIH-owned inventions. 23 May 2024
hares of French immunotherapy company OSE Immunotherapeutics were up almost 15% at 8.33 euros mid-morning on news of an expand partnership with German family-owned pharma major Boehringer Ingelheim. 23 May 2024
Roche’s Japan-based majority-owned company Chugai has launched PiaSky for injection 340 mg (crovalimab), a pH-dependent binding humanized anti-complement (C5) monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), in the Asian country. 23 May 2024
Japanese drugmaker Daiichi Sankyo has established two research institutes: DS Research Institute Boston and DS Research Institute Munich, in Cambridge, Massachusetts, USA and Munich, Germany, respectively. 23 May 2024
Cell engineering company MaxCyte has entered into a strategic platform license agreement with Legend Biotech, another company focused on cell therapies. 23 May 2024
Shares of UK immune-oncology company Roquefort Therapeutics rose almost 24% to 5.51 pence this morning, following the signing of a term sheet to out-license its Midkine antibody portfolio to Dubai-based PDC. 23 May 2024
SpyBiotech, a biotechnology company specializing in innovative vaccine platforms, has entered into a research agreement with the University of Oxford. 23 May 2024
A new cost-cutting campaign from New York-based Pfizer demonstrates the intensity of the firm’s focus on ensuring operational efficiencies. 23 May 2024
Japanese drugmaker Otsuka Pharmaceutical and its US subsidiary have decided to terminate the development of the novel compound AVP-786, which was being studied as a potential treatment for patients with agitation associated with dementia due to Alzheimer's disease. 23 May 2024
Biomarker-driven clinical research and development company Precision for Medicine has announced that Harpreet Singh has joined the Maryland firm as chief medical officer. 22 May 2024
US biotech major Biogen today revealed it plans to acquire privately-held Human Immunology Biosciences (HI-Bio), in a bid to expand its rare disease portfolio. 22 May 2024
Privately-held Swiss company Swixx Biopharma today announced a strategic acquisition of Biopas, one of Latin America’s leading marketing and distribution companies for international biopharmaceutical firms. 22 May 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Italian pharma major Recordati saw its shares rise more than 5% to 52.00 euros in early trading, as it announced a deal to expand its portfolio of marketed rare disease medicines. 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
The European Medicines Agency’s pharmacovigilance committee, PRAC, has started a review of medicines containing finasteride and dutasteride following concerns regarding suicidal ideation (suicidal thoughts) and behaviors. 4 October 2024
Opioid Use Disorder (OUD) is a chronic neurological disorder that is described as the consequences associated with repeated, compulsive use of opioid drugs and prolonged self-administration of opioid drugs. 4 October 2024
Proposals from the National Health Service (NHS) England have been set out for a phased launch of Eli Lilly’s obesity injection Mounjaro/Zepbound (tirzepatide) at the start of a consultation. 4 October 2024
Aspire Pharma, a UK-based niche generics business, has announced the acquisition of all assets from Canute Pharma, further expanding its product range. 4 October 2024
Bristol Myers Squibb has received a new approval from the US Food and Drug Administration for its blockbuster checkpoint blocker, Opdivo (nivolumab). 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
The US Food and Drug Administration (FDA) has granted the Gilead Sciences subsidiary Kite a Regenerative Medicine Advanced Therapy Designation (RMAT) for Yescarta (axicabtagene ciloleucel) for adults with newly-diagnosed, high-risk large B-cell lymphoma (LBCL). 3 October 2024
The US Food and Drug Administration (FDA) has determined the shortage of tirzepatide injection, a glucagon-like peptide 1 (GLP-1) medication, has been resolved. 3 October 2024
Israel’s Teva Pharmaceutical Industries and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, have announced a global licensing deal for the development of an anti PD-1 oncology biosimilar candidate. 3 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Kedrion Biopharma has finalized an agreement with Germany-based Biotest for the long-term commercialization and distribution of Yimmugo (immune globulin) in the USA. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news
Company Spotlight
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.